Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.
about
Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinasesTumor resistance to vascular disrupting agents: mechanisms, imaging, and solutionsThe unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.Hepatocellular Carcinoma: Intra-arterial Delivery of Doxorubicin-loaded Hollow Gold Nanospheres for Photothermal Ablation-Chemoembolization Therapy in Rats.Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck CancerThe Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward.Vascular priming enhances chemotherapeutic efficacy against head and neck cancer.Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents.Combination of nanotechnology with vascular targeting agents for effective cancer therapy.Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review.Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system.Drug-induced amplification of nanoparticle targeting to tumors.
P2860
Q24617675-0B48655B-BF5D-4593-826F-4FC79CE4069BQ26774355-3D4FA636-C318-4F8B-B7F1-026C66D69CF2Q34122191-96168878-6762-4BDB-9B68-DF33DB9C240DQ34746019-3BCC4A6C-8402-4224-8229-04F1FBE6C72DQ36062220-A00AB942-9171-4C02-8A74-06A0A469E712Q36506995-2C6A7A2D-0503-4C16-BD34-E9DD2DEB21D6Q36509433-1D3BB880-1595-4907-894B-BBE2B60B9B8FQ37169566-0ECC1A3F-9F42-4067-9FBA-44A31E8D6C91Q37534993-7814B18C-C970-4F51-8056-BE8B6C96E764Q38150356-E620B01F-378A-4EBF-BBE6-5A78BBB3FFD4Q39368839-20873393-F229-47BF-8468-6646189BFBA1Q41258130-D6070870-D783-4EB4-949E-82DC1D3EBBE8Q47686404-B008FD11-1095-4EB9-AC79-0661E558ABF8Q55131866-2406461B-8E14-4B22-BFA0-04E797DB6BDD
P2860
Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Sequence dependent antitumour ...... n combination with paclitaxel.
@ast
Sequence dependent antitumour ...... n combination with paclitaxel.
@en
type
label
Sequence dependent antitumour ...... n combination with paclitaxel.
@ast
Sequence dependent antitumour ...... n combination with paclitaxel.
@en
prefLabel
Sequence dependent antitumour ...... n combination with paclitaxel.
@ast
Sequence dependent antitumour ...... n combination with paclitaxel.
@en
P2093
P2860
P50
P356
P1476
Sequence dependent antitumour ...... in combination with paclitaxel
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603969
P407
P577
2007-09-11T00:00:00Z